



# SIDDS 2022

## Seoul International Digestive Disease Symposium 2022

*In conjunction with the annual meeting of Korean Society of Gastroenterology*

April 16-17, 2022 **Virtual Congress**



Name	Bo Hyun Kim
Affiliation	Center for Liver and Pancreatobiliary Cancer, National Cancer Center
Country	Republic of Korea
Major Field	Hepatology

### Educational Background

Dr. Bo Hyun Kim graduated from the College of Medicine, Hanyang University, and received a master's degree and Ph.D. from Seoul National University.

### Professional Experience

Following the internship at Asan Medical Center, she completed the internal medicine residency and hepatology fellowship training at Seoul National University Hospital until 2009. She has been working at the Center for Liver and Pancreatobiliary Cancer, National Cancer Center since 2012. She was a visiting scholar at the Division of Gastroenterology, Stanford University in Palo Alto, California, USA in 2017. She is currently a senior scientist and an adjunct associate professor at National Cancer Center and actively involved in translational, investigator-initiated, and industry-sponsored clinical studies on hepatocellular carcinoma.

### Other Experience and Professional Memberships

Dr. Bo Hyun Kim is a member of the Korean Association for the Study of the Liver (KASL), the Korean Liver Cancer Association (KLCA), the European Association for the Study of the Liver (EASL), and the International Liver Cancer Association (ILCA). Dr. Kim served as a member of multiple KASL and KLCA committees, including the scientific committee and the KLCA-NCC clinical practice guideline for the management of hepatocellular carcinoma.

### Main Scientific Publications

Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, Kim DY. Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2021

Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. *J Hepatol*. 2021;74(3):603-612.

Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. *Frontiers in oncology*. 2020;10:542.

Kim BH. Selecting the Right Tool for the Right Job: Which Response Criteria Better Predicts Survival of Patients Treated with Transarterial Radioembolization? *Gut and liver*. 2020;14(6):671-672.

Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STA trial. *J Hepatol*. 2019;70(4):684-691.